Major disparities in access to Molecular Tumour Boards – Lung Cancer Europe
Lung Cancer Europe shared a post on LinkedIn:
“A new consensus statement from the International Association for the Study of Lung Cancer (IASLC) highlights major disparities in access to Molecular Tumour Boards (MTBs) – a key tool in delivering personalised lung cancer care.
‘Global disparities in the successful implementation of MTBs exist, driven by unequal access to molecular diagnostics and supportive multidimensional expertise.’
– IASLC, July 2025
LuCE supports IASLC’s call for:
- Stronger infrastructure
- Broader access to molecular testing
- Use of virtual MTBs to ensure expert input is available to all regardless of location
In Europe, too many people with lung cancer are still being left behind. Personalised care must be a reality everywhere.”
Title: Molecular Tumor Boards: A consensus statement from the International Association for the Study of Lung Cancer
Authors: Mihaela Aldea, Julia K. Rotow, Maria Arcila, Matthew Hatton, Lynette Sholl, Christian Rolfo, Marco Tagliamento, Teodora Radonic, Kurt A. Schalper, Vivek Subbiah, Umberto Malapelle, Anja C. Roden, Rami Manochakian, Ming-Sound Tsao, Helena Linardou, Rina Hui, Silvia Novello, Alastair Greystoke, Anjali Saqi, Sylvie Lantuejoul, David M. Hwang, Kelly Nevins, Murry Wynes, Saiama Waqar, Yuchen Han, Yasushi Yatabe, Wei-Chin Chang, Takuo Hayashi, Tae-Jung Kim, Paul Hofman, Fabio Tavora, Fred R. Hirsch, Valeria Denninghoff, Natasha B. Leighl, Alexander Drilon, Wendy A. Cooper, Sanja Dacic, Pranshu Mohindra, Nick Pavlakis, Fernando Lopez-Rios
Read the Full Article on Journal of Thoracic Oncology.
More posts featuring Lung Cancer Europe.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023